Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Feb 21;18:1534735419828832. doi: 10.1177/1534735419828832

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 5. — Effects of d-methionine on myogenesis (myogenin and MyoD) and specific E3-ubiquitin ligase (MAFbx and MuRF-1) mRNA levels in cisplatin-induced C2C12 myotube atrophy. C2C12 myotubes were treated with Dulbecco’s modified Eagle medium (DMEM), 50 µM cisplatin or 50 µM cisplatin + 5 mM d-methionine for up to 24 hours. (A) Cellular morphological changes. (B) Real-time polymerase chain reaction. The mRNA expression levels of MAFbx, MuRF-1, myogenin, and MyoD were normalized according to the amount of β-actin. Results are representative of 3 independent experiments. Values are presented as Mean ± SD. *Indicates statistical significance when compared with the saline-treated group (P < .05). ^#Indicates statistical significance when compared with the cisplatin-treated group (P < .05).